-
公开(公告)号:US20140135332A1
公开(公告)日:2014-05-15
申请号:US14112735
申请日:2012-04-20
Applicant: David John Haydon , Lloyd George Czaplewski , Neil Robert Stokes , David Davies , Ian Collins , James T Palmer , Jeffrey Peter Mitchell , Gary Robert William Pitt , Daniel Offermann
Inventor: David John Haydon , Lloyd George Czaplewski , Neil Robert Stokes , David Davies , Ian Collins , James T Palmer , Jeffrey Peter Mitchell , Gary Robert William Pitt , Daniel Offermann
IPC: A61K31/5377 , A61K31/506 , A61K31/437 , A61K31/4439 , A61K31/433 , A61K31/427 , A61K31/421 , C07D513/04 , C07D413/12 , C07D285/08 , C07D277/30 , C07D263/32 , A61K31/496 , A61K31/426
CPC classification number: A61K31/5377 , A61K31/166 , A61K31/421 , A61K31/4245 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/496 , A61K31/506 , C07D263/32 , C07D271/06 , C07D277/24 , C07D277/30 , C07D285/08 , C07D413/06 , C07D413/10 , C07D413/12 , C07D417/06 , C07D417/12 , C07D513/04
Abstract: The present invention provides compounds of Formula (I): and salts, racemates, isomers, diastereoisomers, enantiomers, hydrates, solvates, N-oxides, pharmaceutically acceptable derivatives or prodrugs thereof. Also provided the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.
Abstract translation: 本发明提供式(I)的化合物:及其盐,外消旋物,异构体,非对映异构体,对映异构体,水合物,溶剂化物,N-氧化物,其药学上可接受的衍生物或前药。 还提供这些化合物作为抗菌剂的用途,包含它们的组合物及其制备方法。
-
公开(公告)号:US08415383B2
公开(公告)日:2013-04-09
申请号:US12679334
申请日:2008-09-22
Applicant: David John Haydon , Ian Collins , Lloyd George Czaplewski
Inventor: David John Haydon , Ian Collins , Lloyd George Czaplewski
CPC classification number: C07D277/34 , A61K31/4245 , A61K31/427 , A61K31/429 , A61K31/433 , C07D271/07 , C07D277/64 , C07D285/08 , C07D417/12
Abstract: Compounds of formula (IA) or (IB) have antibacterial activity: wherein W is ═C(H)— or ═N—; R3 is a radical of formula -(Alk1)m-(Z1)p-(Alk2)n-Q wherein m, p and n are independently 0 or 1, provided that at least one of m, p and n is 1, Z1 is —O—, —S—, —S(O)—, —S(O2)—, —NH—, —N(CH3)—, —N(CH2CH3)—, —C(—O)—, —0—(C═O)—, —C(═O)—O—, or an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted divalent bicyclic carbocyclic or heterocyclic radical having 5 to 10 ring atoms; Alk1 and Alk2 are optionally substituted C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene radicals, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —S(O2)—, —NH—, —N(CH3)—, Or —N(CH2CH3)—; and Q is hydrogen, halogen, nitrile, or hydroxyl, or an optionally substituted monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted bicyclic carbocyclic or heterocyclic radical having 5 to 10 ring atoms; R4 and R5 are optional substituents; and R2, R6 and R7 are independently hydrogen or a radical of formula -(Alk3)x-(Z2)y-(Alk4)z-H wherein x, y and z are independently 0 or 1, Z2 is —O—, —S—, —S(O)—, —S(O2)—, —NH—, —N(CH3)—, —N(CH2CH3)—, —C(—O)—, —0—(C═O)— or —C(═O)—O—; Alk3 and Alk4 are optionally substituted C1-C3 alkylene, C2-C3 alkenylene, or C2-C3 alkynylene radicals, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —S(O2)—, —NH—, —N(CH3)—, or —N(CH2CH3)—.
-
公开(公告)号:US20100173933A1
公开(公告)日:2010-07-08
申请号:US12293608
申请日:2007-03-22
Applicant: David Ryall Brown , Ian Collins , Lloyd George Czaplewski , David John Haydon
Inventor: David Ryall Brown , Ian Collins , Lloyd George Czaplewski , David John Haydon
IPC: A61K31/437 , C07D277/62 , C07D471/04 , C07D263/34 , C07D271/06 , A61K31/428 , A61K31/421 , A61K31/41 , A61P31/04
CPC classification number: C07C235/46 , A01N37/40 , A01N41/04 , A01N43/08 , A01N43/10 , A01N43/40 , A01N43/42 , A01N43/76 , A01N43/78 , A01N43/82 , A01N43/90 , A61K31/166 , A61K31/341 , A61K31/343 , A61K31/352 , A61K31/381 , A61K31/4025 , A61K31/4155 , A61K31/4178 , A61K31/4184 , A61K31/4192 , A61K31/4196 , A61K31/422 , A61K31/423 , A61K31/4245 , A61K31/427 , A61K31/428 , A61K31/429 , A61K31/433 , A61K31/44 , A61K31/4422 , A61K31/4523 , A61K31/4709 , C07C255/16 , C07C309/73 , C07C2601/02 , C07C2601/14 , C07C2601/18 , C07D213/30 , C07D213/81 , C07D215/12 , C07D215/14 , C07D231/12 , C07D233/64 , C07D249/04 , C07D261/08 , C07D263/32 , C07D263/56 , C07D271/06 , C07D271/10 , C07D277/24 , C07D277/32 , C07D277/64 , C07D307/42 , C07D307/56 , C07D319/20 , C07D333/06 , C07D333/12 , C07D333/16 , C07D333/56 , C07D413/04 , C07D417/04 , C07D417/06 , C07D417/14 , C07D471/04 , C07D498/04 , C07D513/04
Abstract: Compounds of formula (I) have antibacterial activity: wherein R represents hydrogen or 1, 2 or 3 optional substituents; W is ═C(R1)— or ═N—; R1 is hydrogen or an optional substituent and R2 is hydrogen, methyl, or fluorine; or R1 and R2 taken together are —CH2—, —CH2CH2—, —O—, or, in either orientation, —O—CH2— or —OCH2CH2—; R3 is a radical of formula -(Alk1)m-(Z)p-(Alk2)n-Q wherein m, p and n are independently 0 or 1, provided that at least one of m, p and n is 1, Z is —O—, —S—, —S(O)—, —S(O2)—, —NH—, —N(CH3)—, —N(CH2CH3)—, —C(═O)—, —O—(C═O)—, —C(═O)—O—, or an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted divalent bicyclic heterocyclic radical having 5 to 10 ring atoms; Alk1 and Alk2 are optionally substituted C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene radicals, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —S(O2)—, —NH—, —N(CH3)—, or —N(CH2CH3)—; and Q is hydrogen, halogen, nitrile, or hydroxyl or an optionally substituted monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted bicyclic heterocyclic radical having 5 to 10 ring atoms.
Abstract translation: 式(I)化合物具有抗菌活性:其中R表示氢或1,2或3个任选的取代基; W是≡C(R1) - 或=N-; R1是氢或任选的取代基,R 2是氢,甲基或氟; 或R 1和R 2一起为-CH 2 - , - CH 2 CH 2 - , - O-,或者在任一取向为-O-CH 2 - 或-OCH 2 CH 2 - ; R3是式 - (Alk1)m-(Z)p-(Alk2)nQ的基团,其中m,p和n独立地为0或1,条件是m,p和n中的至少一个为1,Z为 - (O) - , - S(O 2) - , - NH - , - N(CH 3) - , - N(CH 2 CH 3) - , - (C = O) - , - C(= O)-O-,或具有3至6个环原子的任选取代的二价单环碳环或杂环基; 或具有5至10个环原子的任选取代的二价双环杂环基; Alk1和Alk2是任选取代的C 1 -C 6亚烷基,C 2 -C 6亚烯基或C 2 -C 6亚炔基,其可以任选地被-O - , - S - , - S(O) - , - S( O,-N(CH 3) - 或-N(CH 2 CH 3) - ; 和Q是氢,卤素,腈或羟基或任选取代的具有3-6个环原子的单环碳环或杂环基; 或具有5〜10个环原子的任意取代的双环杂环基。
-
公开(公告)号:US5965697A
公开(公告)日:1999-10-12
申请号:US936387
申请日:1997-09-25
Applicant: Lloyd George Czaplewski , Michael George Hunter , Richard Mark Edwards , Keith Martyn Dawson
Inventor: Lloyd George Czaplewski , Michael George Hunter , Richard Mark Edwards , Keith Martyn Dawson
CPC classification number: C07K14/523 , A61K38/00
Abstract: This invention relates to mutants of human RANTES (hRANTES) which, relative to the wild-type molecule, have a reduced tendency to aggregate into large multimeric complexes at physiological ionic strength and pH, and are less pro-inflammatory.
Abstract translation: 本发明涉及人RANTES(hRANTES)的突变体,其相对于野生型分子在生理离子强度和pH下具有降低的聚集成大多聚体复合物的趋势,并且较少促炎症。
-
公开(公告)号:US08865736B2
公开(公告)日:2014-10-21
申请号:US13304748
申请日:2011-11-28
Applicant: David Ryall Brown , Ian Collins , Lloyd George Czaplewski , David John Haydon
Inventor: David Ryall Brown , Ian Collins , Lloyd George Czaplewski , David John Haydon
IPC: A01N43/44 , A61K31/352 , A61K31/381 , A61K31/4192 , A61K31/422 , C07D261/08 , C07D277/24 , A61K31/341 , A61K31/4523 , A61K31/343 , A61K31/428 , C07D413/04 , C07D277/64 , C07D263/56 , A61K31/4178 , C07D231/12 , A61K31/4245 , A61K31/4709 , A61K31/166 , C07D498/04 , C07D471/04 , C07D417/14 , C07D307/42 , C07D213/30 , C07D333/12 , A61K31/4184 , A61K31/433 , C07D417/06 , A61K31/4422 , A61K31/44 , C07D271/10 , C07D215/12 , C07D417/04 , C07D319/20 , A61K31/4155 , C07D513/04 , C07D263/32 , C07D249/04 , C07D233/64 , C07D333/06 , A61K31/4196 , C07D213/81 , C07D333/56 , A61K31/429 , C07D277/32 , C07D271/06 , A61K31/423 , A61K31/4025 , A61K31/427
CPC classification number: C07C235/46 , A01N37/40 , A01N41/04 , A01N43/08 , A01N43/10 , A01N43/40 , A01N43/42 , A01N43/76 , A01N43/78 , A01N43/82 , A01N43/90 , A61K31/166 , A61K31/341 , A61K31/343 , A61K31/352 , A61K31/381 , A61K31/4025 , A61K31/4155 , A61K31/4178 , A61K31/4184 , A61K31/4192 , A61K31/4196 , A61K31/422 , A61K31/423 , A61K31/4245 , A61K31/427 , A61K31/428 , A61K31/429 , A61K31/433 , A61K31/44 , A61K31/4422 , A61K31/4523 , A61K31/4709 , C07C255/16 , C07C309/73 , C07C2601/02 , C07C2601/14 , C07C2601/18 , C07D213/30 , C07D213/81 , C07D215/12 , C07D215/14 , C07D231/12 , C07D233/64 , C07D249/04 , C07D261/08 , C07D263/32 , C07D263/56 , C07D271/06 , C07D271/10 , C07D277/24 , C07D277/32 , C07D277/64 , C07D307/42 , C07D307/56 , C07D319/20 , C07D333/06 , C07D333/12 , C07D333/16 , C07D333/56 , C07D413/04 , C07D417/04 , C07D417/06 , C07D417/14 , C07D471/04 , C07D498/04 , C07D513/04
Abstract: Compounds of formula (I) have antibacterial activity: wherein R represents hydrogen or 1, 2 or 3 optional substituents; W is ═C(R1)—; R1 is hydrogen and R2 is hydrogen, methyl, or fluorine; or R1 and R2 taken together are —CH2—, —CH2CH2, —O—, or, in either orientation, —O—CH2— or —OCH2CH2—; and R3 is a radical of formula -(Alk1)m-(Z)p-(Alk2)n-Q.
Abstract translation: 式(I)化合物具有抗菌活性:其中R表示氢或1,2或3个任选的取代基; W为═C(R1) - ; R1是氢,R2是氢,甲基或氟; 或R 1和R 2一起为-CH 2 - , - CH 2 CH 2,-O-,或者在任一取向为-O-CH 2 - 或-OCH 2 CH 2 - ; 并且R3是式 - (Alk1)m-(Z)p-(Alk2)n-Q的基团。
-
公开(公告)号:US20110212120A1
公开(公告)日:2011-09-01
申请号:US10503136
申请日:2003-02-11
Applicant: Lloyd George Czaplewski , Andrew Stephen Waller
Inventor: Lloyd George Czaplewski , Andrew Stephen Waller
IPC: A61K39/02 , C07H21/00 , C12N15/63 , C12N5/10 , C12N1/00 , C12N9/80 , C12Q1/68 , C12Q1/34 , A61P37/04 , A61P31/04
CPC classification number: C12N9/80 , A61K39/00 , A61K2039/53
Abstract: Nucleic acid encoding a novel bacterial polypeptide ykuR, the isolated ykuR polypeptide, its expression from host cells, and its use in screening for potential antibacterial agents. Inhibition of ykuR activity results in inhibition of bacterial growth.
Abstract translation: 编码新的细菌多肽ykuR的核酸,分离的ykuR多肽,其从宿主细胞的表达,以及其在筛选潜在抗菌剂中的用途。 抑制ykuR活性导致抑制细菌生长。
-
公开(公告)号:US20100311766A1
公开(公告)日:2010-12-09
申请号:US12747753
申请日:2008-12-12
Applicant: David John Haydon , Lloyd George Czaplewski
Inventor: David John Haydon , Lloyd George Czaplewski
IPC: A61K31/497 , C07D513/04 , A61K31/444 , A61P31/04 , A01N43/40 , A01N43/60 , A01P1/00
CPC classification number: C07D513/04
Abstract: Compounds of formula (I) have antibacterial activity wherein: m is O or 1; Q is hydrogen or cyclopropyl; AIk is an optionally substituted, divalent C1-C3 alkylene, C2-C3 alkenylene or C2-C3 alkynylene radical; X is —C(═O)NH— or —C(═O)O—; R2 and R3 are as defined in the specification.
Abstract translation: 式(I)化合物具有抗菌活性,其中:m为0或1; Q是氢或环丙基; Alk是任选取代的二价C 1 -C 3亚烷基,C 2 -C 3亚烯基或C 2 -C 3亚炔基; X是-C(= O)NH-或-C(= O)O-; R2和R3如说明书中所定义。
-
公开(公告)号:US20100305067A1
公开(公告)日:2010-12-02
申请号:US12747811
申请日:2008-12-12
Applicant: David John Haydon , Lloyd George Czaplewski
Inventor: David John Haydon , Lloyd George Czaplewski
IPC: A61K31/4439 , C07D417/10 , C07D417/14 , A01N43/40 , A61K31/437 , A01N43/90 , A61K31/5383 , A61K31/69 , A01N55/08 , A61P31/04 , A01P1/00
CPC classification number: C07D417/04 , C07D277/82 , C07D417/14 , C07D471/04 , C07D498/04 , C07D513/04
Abstract: Compound of formula (I) have antibacterial activity: wherein: m is 0 or 1; Q is hydrogen or cyclopropyl; AIk is an optionally substituted, divalent C1-C6 alkylene, alkenylene or alkynylene radical which may contain an ether (—O—), thioether (—S—) or amino (—NR)— link, wherein R is hydrogen, —CN or C1-C3 alkyl; X is —C(═O)NR6—, or —C(═O)O— wherein R6 is hydrogen, optionally substituted C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; Z1 is —N═ or —CH═Z2 is —N═ or —C(R1)═; R1 is hydrogen, methyl, ethyl, ethenyl, ethynyl, methoxy, mercapto, mercaptomethyl, halo, fully or partially fluorinated (C1-C2)alkyl, (C1-C2Jalkoxy or (C1-C2)alkylthio, nitro, or nitrile (—CN); R2 is a group Q1-[Alk1]q-Q2-, wherein q is 0 or 1; AIk1 is an optionally substituted, divalent, straight chain or branched C1-C6 alkylene, or C2-C6 alkenylene or C2-C6 alkynylene radical which may contain or terminate in an ether (—O—), thioether (—S—) or amino (—NR)— link; Q2 is an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 5 or 6 ring atoms or an optionally substituted divalent bicyclic carbocyclic or heterocyclic radical having 9 or 10 ring atoms; Q1 is hydrogen, an optional substituent, or an optionally substituted carbocyclic or heterocyclic radical having 3-7 ring atoms.
Abstract translation: 式(I)化合物具有抗菌活性:其中:m为0或1; Q是氢或环丙基; Alk是可以含有醚(-O-),硫醚(-S-)或氨基(-NR) - 连接的任意取代的二价C 1 -C 6亚烷基,亚烯基或亚炔基,其中R是氢,-CN或 C1-C3烷基; X是-C(= O)NR 6 - 或-C(= O)O-,其中R 6是氢,任选取代的C 1 -C 6烷基,C 2 -C 6烯基或C 2 -C 6炔基; Z1是-N =或-CH = Z2是-N =或-C(R1)=; R 1是氢,甲基,乙基,乙烯基,乙炔基,甲氧基,巯基,巯基甲基,卤素,完全或部分氟化的(C1-C2)烷基,(C1-C2烷氧基或(C1-C2)烷硫基,硝基或腈 ); R2是Q1- [Alk1] q-Q2-,其中q是0或1; Alk1是任选取代的,二价的,直链或支链的C 1 -C 6亚烷基或C 2 -C 6亚烯基或C 2 -C 6亚炔基 可以含有或终止于醚(-O-),硫醚(-S-)或氨基(-NR))连接基团的基团; Q 2是具有5或6个环原子的任选取代的二价单环碳环或杂环基团, 具有9或10个环原子的取代的二价双环碳环或杂环基; Q 1是氢,任选的取代基或具有3-7个环原子的任选取代的碳环或杂环基。
-
公开(公告)号:US08389516B2
公开(公告)日:2013-03-05
申请号:US13154592
申请日:2011-06-07
Applicant: David John Haydon , Lloyd George Czaplewski , Nicholas John Palmer , Dale Robert Mitchell , John Frederick Atherall , Christopher Richard Steele , Tamara Ladduwahetty
Inventor: David John Haydon , Lloyd George Czaplewski , Nicholas John Palmer , Dale Robert Mitchell , John Frederick Atherall , Christopher Richard Steele , Tamara Ladduwahetty
IPC: A61K31/5377 , A61K31/501 , A61K31/497 , A61K31/496 , A61K31/506 , A61K31/4436 , A61K31/428 , A61K31/429 , C07D239/42
CPC classification number: C07D417/04 , C07D417/14 , Y02P20/582
Abstract: Compounds of formula (I) have antibacterial activity: wherein: m is 0 or 1; Q is hydrogen or cyclopropyl; Alk is an optionally substituted, divalent C1-C6 alkylene, alkenylene or alkynylene radical which may contain an ether (—O—), thioether (—S—) or amino (—NR)— link, wherein R is hydrogen, —CN or C1-C3 alkyl; X is —C(═O)NR6—, —S(O)NR6—, —C(═O)O— or —S(═O)O— wherein R6 is hydrogen, optionally substituted C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -Cyc, or —(C1-C3 alkyl)-Cyc wherein Cyc is optionally substituted monocyclic carbocyclic or heterocyclic having 3-7 ring atoms; Z is N or CH, or CF; R2 and R3 are as defined in the description.
Abstract translation: 式(I)化合物具有抗菌活性:其中:m为0或1; Q是氢或环丙基; Alk是可以含有醚(-O-),硫醚(-S-)或氨基(-NR) - 连接的任意取代的二价C1-C6亚烷基,亚烯基或亚炔基,其中R是氢,-CN或 C1-C3烷基; X是-C(= O)NR 6 - , - S(O)NR 6 - , - C(= O)O-或-S(= O)O-,其中R 6是氢,任选取代的C 1 -C 6烷基, C6链烯基,C2-C6炔基,-Cyc或 - (C1-C3烷基)-Cyc,其中Cyc是具有3-7个环原子的任选取代的单环碳环或杂环; Z是N或CH,或CF; R2和R3如说明书中所定义。
-
公开(公告)号:US08299065B2
公开(公告)日:2012-10-30
申请号:US12747811
申请日:2008-12-12
Applicant: David John Haydon , Lloyd George Czaplewski
Inventor: David John Haydon , Lloyd George Czaplewski
IPC: A61K31/5365 , A61K31/4427 , A61K31/4196 , A61K31/497 , A61K31/428 , A61K31/47 , A61K31/5377 , A61K31/506 , C07D417/14 , C07D417/02 , C07D265/28 , C07D241/10 , C07D277/62 , C07D401/14 , C07D265/30 , C07D241/04 , C07D239/20
CPC classification number: C07D417/04 , C07D277/82 , C07D417/14 , C07D471/04 , C07D498/04 , C07D513/04
Abstract: Compound of formula (I) have antibacterial activity: wherein: m is 0 or 1; Q is hydrogen or cyclopropyl; AIk is an optionally substituted, divalent C1-C6 alkylene, alkenylene or alkynylene radical which may contain an ether (—O—), thioether (—S—) or amino (—NR)— link, wherein R is hydrogen, —CN or C1-C3 alkyl; X is —C(═O)NR6—, or —C(═O)O— wherein R6 is hydrogen, optionally substituted C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; Z1 is —N═ or —CH═Z2 is —N═ or —C(R1)═; R1 is hydrogen, methyl, ethyl, ethenyl, ethynyl, methoxy, mercapto, mercaptomethyl, halo, fully or partially fluorinated (C1-C2)alkyl, (C1-C2JaIkoxy or (C1-C2)alkylthio, nitro, or nitrile (—CN); R2 is a group Q1-[Alk1]q-Q2-, wherein q is 0 or 1; AIk1 is an optionally substituted, divalent, straight chain or branched C1-C6 alkylene, or C2-C6 alkenylene or C2-C6 alkynylene radical which may contain or terminate in an ether (—O—), thioether (—S—) or amino (—NR)— link; Q2 is an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 5 or 6 ring atoms or an optionally substituted divalent bicyclic carbocyclic or heterocyclic radical having 9 or 10 ring atoms; Q1 is hydrogen, an optional substituent, or an optionally substituted carbocyclic or heterocyclic radical having 3-7 ring atoms.
Abstract translation: 式(I)化合物具有抗菌活性:其中:m为0或1; Q是氢或环丙基; Alk是可以含有醚(-O-),硫醚(-S-)或氨基(-NR) - 连接的任意取代的二价C 1 -C 6亚烷基,亚烯基或亚炔基,其中R是氢,-CN或 C1-C3烷基; X是-C(= O)NR 6 - 或-C(= O)O-,其中R 6是氢,任选取代的C 1 -C 6烷基,C 2 -C 6烯基或C 2 -C 6炔基; Z1是-N =或-CH = Z2是-N =或-C(R1)=; R 1是氢,甲基,乙基,乙烯基,乙炔基,甲氧基,巯基,巯基甲基,卤素,完全或部分氟化的(C1-C2)烷基,(C1-C2-烷氧基或(C1-C2)烷硫基,硝基或腈 ); R2是Q1- [Alk1] q-Q2-,其中q是0或1; Alk1是任选取代的,二价的,直链或支链的C 1 -C 6亚烷基或C 2 -C 6亚烯基或C 2 -C 6亚炔基 可以含有或终止于醚(-O-),硫醚(-S-)或氨基(-NR))连接基团的基团; Q 2是具有5或6个环原子的任选取代的二价单环碳环或杂环基团, 具有9或10个环原子的取代的二价双环碳环或杂环基; Q 1是氢,任选的取代基或具有3-7个环原子的任选取代的碳环或杂环基。
-
-
-
-
-
-
-
-
-